RxDoctor Payments Data

Robert Skala

Family Medicine · Eagle River, AKNPI 1598825663

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,800 of the $38,074 with a category attached, or 73.0%. AstraZeneca accounts for 70.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $21,093 and has fallen 98.6% since, to $287 in 2025. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,074in general payments, 2019–2025

Across 203 payments — averaging $187.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$27K
  • Boehringer Ingelheim$6K
  • Lilly USA, LLC$3K
  • AbbVie$529
  • Novo Nordisk$421
  • Tandem Diabetes Care, Inc.$366
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$2,2506%
  • Speaking & faculty fees$27,80073%
  • Travel & lodging$2,7417%
  • Food & beverage$5,28314%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,074 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.

See all family medicine providers in Alaska

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$156,480
Humira PenAdalimumab11$104,237
JardianceEmpagliflozin56$87,643
FarxigaDapagliflozin Propanediol39$58,615
OzempicSemaglutide32$48,610
EliquisApixaban27$34,513
RybelsusSemaglutide14$27,645
JanuviaSitagliptin Phosphate17$27,334
Tresiba Flextouch U-100Insulin Degludec16$19,139
GlyxambiEmpagliflozin/Linagliptin13$16,708
Combivent RespimatIpratropium/Albuterol Sulfate19$16,196
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,603
KerendiaFinerenone12$14,664
Novolog FlexpenInsulin Aspart25$9,646
Carvedilol ErCarvedilol Phosphate15$9,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$2,811$156,480111 claims
Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat$5,670$120,54688 claims
Novo NordiskOzempic, Rybelsus$421$76,25546 claims
AstraZenecaFarxiga, Breztri Aerosphere$26,675$74,21858 claims
PfizerEliquis$23$34,51327 claims
MerckJanuvia$202$27,33417 claims
BayerKerendia$151$14,66412 claims
AbbVieSynthroid$529$1,56119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.

Other family medicine in Eagle River

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →